ClinicalTrials.gg
TerminatedNCT00831441APPRAISE-2Updated Jan 27, 2016Results posted

Phase III Acute Coronary Syndrome

A Phase 3 interventional study of Apixaban and Placebo in Acute Coronary Syndrome, sponsored by Bristol-Myers Squibb. Terminated at 1,014 sites in 40 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-01-27.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
7,484
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 265 studies in Acute Coronary Syndrome with a site in United States — 14 open to participants now, 21 under way, 2 of them phase 3. Acute Coronary Syndrome · United States.

Enrollment
19th of 186
7,484 · median 150
Started
2009
with 14 others
Phase 3
40 of 265
1 open now
Registered
55th of 265
by date

Among the 265 studies in Acute Coronary Syndrome with a site in United States, this one is the 19th largest by enrollment of the 186 interventional ones that give a count, is one of 15 that started in 2009, is one of 40 in phase 3, and was the 55th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

14 of the 265 studies in Acute Coronary Syndrome with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 265 studies in Acute Coronary Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine if apixaban is superior to placebo for preventing cardiovascular death, non-fatal myocardial infarction, or ischemic stroke in subjects with a recent acute coronary syndrome

03

Conditions studied

  • Acute Coronary Syndrome

Keywords

  • NOS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Acute coronary syndrome (ACS)
  • Clinically stable
  • Receiving standard of care for ACS

Exclusion criteria

Exclusion Criteria:

  • Severe hypertension
  • Active bleeding or high risk for major bleeding
  • \< 9 g/dL
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
7,484 participants (actual)

Study arms

  • Active comparator
    Apixaban

    Drug: Apixaban

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Tablets, Oral, 5 mg, twice daily, until study end

    Also known as: BSM-562247

  • DrugPlacebo

    Tablets, Oral, 0 mg, twice daily, until study end

06

What researchers measure

Primary outcomes

  1. Event Rate of Cardiovascular Death, Myocardial Infarction, or Ischemic Stroke During the Intended Treatment Period - Randomized Participants

    Event rate was percent of participants with an event of cardiovascular (CV) death, myocardial infarction (MI), or ischemic stroke (number of participants with event/number randomized) per 100 patient (100-pt) years. Study was terminated early and last patient, last visit was in Year 2. Only events confirmed by the adjudication committee were included in the analyses. CV death included deaths due to CV causes (eg, cardiogenic shock, heart failure, arrhythmia/sudden death, cardiac rupture, ischemic stroke, pulmonary embolism, venous/arterial thrombotic events) and other sudden deaths for which an alternative cause was not identified. Intended Treatment Period: the period that started on the day of randomization and ended at the efficacy cut-off date (cut-off date: the date all sites were informed that study drug should be discontinued for all participants, 18 November 2010).

    Time frame: Randomization (Day 1) to first event (CV death, MI, ischemic stroke), up to March 2011, approximately 2 years

  2. Event Rate of Confirmed Major Bleeding Using Thrombolysis in Myocardial Infarction (TIMI) Criteria During the Treatment Period - Treated Participants

    TIMI Major Bleed Criteria: Fatal bleeding, intracranial hemorrhage, and clinically overt bleeding with a hemoglobin (Hgb) drop of ≥ 5 grams per deciliter (g/dL), or ≥15% absolute decrease in hematocrit. To account for transfusions, Hgb measurements were adjusted for transfusions. A transfusion of 1 unit of blood was assumed to result in an increase by 1 g/dL in Hgb or 3% in hematocrit. Event rate was percent of participants with an event of Major Bleed as per TIMI (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. Treatment Period=events with onset from first dose to last dose plus 2 days.

    Time frame: From first dose to first occurrence of event (TIMI major bleeding) during Treatment Period (first dose to last dose + 2 days), up to March 2011, approximately 2 years

Secondary outcomes

  1. Event Rate of Unstable Angina (UA) During the Intended Treatment Period - Randomized Participants

    Unstable Angina (UA) defined as worsening or recurrent severe or repetitive angina symptoms at rest lasting at least 10 minutes with at least 2 of the following: New and dynamic electrocardiogram (ECG) changes; angina symptoms leading to inpatient hospitalization; angina symptoms leading to an unplanned or urgent cardiac catheterization, with or without revascularization, that showed evidence of hemodynamically and clinically significant stenosis. Event rate was percent of participants with an event of unstable angina (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. Intended Treatment Period: the period that started on the day of randomization and ended at the efficacy cut-off date (cut-off date: the date all sites were informed that study drug should be discontinued for all participants, 18 November 2010).

    Time frame: Randomization (Day 1) to first event of UA, up to March 2011, approximately 2 years

  2. Event Rate of Stroke During the Intended Treatment Period - Randomized Participants

    Event rate was percent of participants with an event of stroke (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. Diagnosis of stroke required a new, non-traumatic, focal neurological deficit of sudden onset, lasting at least 24 hours that was not due to a readily identifiable non-vascular cause (ie, brain tumor). All strokes were classified as hemorrhagic (documentation on imaging (eg computed tomography scan or magnetic resonance imaging) of hemorrhage in the cerebral parenchyma, or a subdural or subarachnoid hemorrhage), non-hemorrhagic/ischemic stroke, ischemic stroke with hemorrhagic conversion, or type unknown. Intended Treatment Period: the period that started on the day of randomization (Day 1) and ended at the efficacy cut-off date (notification of study termination).

    Time frame: Randomization (Day 1) to first event (stroke), up to March 2011, approximately 2 years

  3. Event Rate of Myocardial Infarction (MI) During the Intended Treatment Period - Randomized Participants

    MI took into account whether the participant had a recent percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery. Selected key criteria: Elevation of cardiac biomarkers (eg, Creatine Kinase MB fraction (CKMB), Troponin T, Troponin I) above the upper reference limit (URL) plus ischemic symptoms, ECG changes, or imaging evidence of new loss of viable myocardium or new regional wall motion abnormality; Death of CV etiology with new ST-segment elevation or left bundle branch block (LBBB) or fresh intracoronary thrombus by angiography or at autopsy occurring before biomarkers could be obtained or before their appearance in the blood; Following a PCI, elevation of cardiac biomarkers more than 3\*URL; Following CABG surgery, elevation of cardiac biomarkers more than 5\*URL; New, significant (≥0.04 s) Q waves in ≥2 contiguous leads; Pathologic findings of acute MI. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off notice.

    Time frame: Randomization (Day 1) to first event (MI), up to March 2011, approximately 2 years

  4. Event Rate of Stent Thrombosis During the Intended Treatment Period - Randomized Participants

    Stent thrombosis: Definite stent thrombosis considered to have occurred by either angiographic or pathological confirmation; Probable stent thrombosis considered to have occurred in the following cases: any unexplained death within the first 30 days after stent implantation; irrespective of the time after the procedure, any MI that was related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause; Possible stent thrombosis considered to have occurred with any unexplained death from 30 days after intracoronary stenting until end of study (in Year 2). Event rate was percent of participants with an event of stent thrombosis (number with event/number randomized) per 100-pt years. Only events confirmed by the adjudication committee were included in the analyses. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off notice of study termination.

    Time frame: Randomization (Day 1) to first event (stent thrombosis), up to March 2011, approximately 2 years

  5. Event Rate of Composite of Cardiovascular Death, Myocardial Infarction, Unstable Angina, or Ischemic Stroke During the Intended Treatment Period - Randomized Participants

    Event rate was percent of participants with an event of CV death, MI, unstable angina (UA), or ischemic stroke (number of participants with event/number randomized) per 100-pt years. Only events confirmed by the adjudication committee were included in the analyses. Each type of event was counted once per participant, but participants could have been counted in multiple categories. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off date (notification of study termination).

    Time frame: Randomization (Day 1) to first event (CV death, MI, UA, Ischemic Stroke, up to March 2011, approximately 2 years

  6. Event Rate of Composite of Cardiovascular Death, Fatal Bleed, Myocardial Infarction, or Stroke During the Intended Treatment Period - Randomized Participants

    Event rate was percent of participants with an event of CV death, fatal bleed, MI, or stroke (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. CV death included deaths due to CV causes; Diagnosis of stroke required a new, non-traumatic, focal neurological deficit of sudden onset, lasting at least 24 hours that was not due to a readily identifiable non-vascular cause; Fatal bleeding defined as bleeding that Adjudication Committee determined was the primary cause of death or contributed directly to death; MI took into account whether the participant had a recent PCI or CABG surgery. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off date (notification of study termination).

    Time frame: Randomization (Day 1) to first event (CV death, Fatal Bleed, MI, or stroke), up to March 2011, approximately 2 years

  7. Event Rate of Composite of All-Cause Death, Myocardial Infarction, or Stroke During the Intended Treatment Period - Randomized Participants

    Cause of death was determined by the principal condition that caused the death, not the immediate mode of death. CV death: included deaths due to CV causes. Non-CV death: included non-CV deaths caused primarily by a malignancy, infection, bleeding, trauma, non-CV system organ failure, or non-CV surgery. Unknown: included deaths that were not attributable to one of the above categories of CV death or to a non-CV cause. MI accounted whether the participant had a recent PCI or CABG surgery. Diagnosis of stroke required a new, non-traumatic, focal neurological deficit of sudden onset, lasting at least 24 hours that was not due to a readily identifiable non-vascular cause. Only events confirmed by the adjudication committee were included in analyses. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off date (notification of study termination).

    Time frame: Randomization (Day 1) to first event (All Cause Death, MI, or Stroke), up to March 2011, approximately 2 years

  8. Event Rate of Confirmed Major Bleeding Using International Society on Thrombosis and Hemostasis (ISTH) Criteria During the Treatment Period - Treated Participants

    ISTH Criteria: Acute clinically overt bleeding defined as new onset, visible bleeding or signs or symptoms suggestive of bleeding confirmed by imaging techniques, which can detect the presence of blood (eg, ultrasound, CT, MRI). Major bleeding: acute clinically overt bleeding accompanied by one or more of the following: A decrease in Hgb of 2 g/dL or more over 24 hours; A transfusion of 2 or more units of packed red blood cells (RBCs); Bleeding that occurs in at least one of the following sites: intracranial, intraspinal, intraocular (within the corpus of the eye; thus, a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal; Bleeding that was fatal. Bleeding events were adjudicated by the Adjudication Committee. Event rate was percent of participants with an event (number with event/number randomized) per 100-pt years. Treatment Period=events with onset from first dose to last dose plus 2 days.

    Time frame: From first dose to first occurrence of event (ISTH major bleed) during Treatment Period (first dose to last dose + 2 days), up to March 2011, approximately 2 years

  9. Event Rate of Confirmed Major Bleeding or Clinically Relevant Non-Major Bleeding (CRNM) Using ISTH Criteria During the Treatment Period - Treated Participants

    ISTH Major bleed: acute clinically overt bleeding accompanied by one or more of the following: A decrease in Hgb of 2 g/dL or more over 24 hours; A transfusion of 2 or more units of packed RBCs; Bleeding that occurs in at least one of the following critical sites: intracranial, intraspinal, intraocular (within the corpus of the eye), pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal; Bleeding that was fatal. CRNM: acute clinically overt bleeding that did not satisfy additional criteria required for the bleeding event to be defined as a major bleeding event and meets at least one of the following: Hospital admission for bleeding; Physician guided medical or surgical treatment for bleeding; Change in anti-thrombotic treatment (anticoagulant or antiplatelet) therapy. Bleeding events were adjudicated by the Adjudication Committee. Treatment Period=events with onset from first dose to last dose plus 2 days.

    Time frame: From first dose to first occurrence of event (ISTH major or CRNM bleed) during Treatment Period (first dose to last dose + 2 days), up to March 2011, approximately 2 years

  10. Event Rate of All Bleeding Reported by the Investigator During the Treatment Period - Treated Participants

    Bleeding events were adjudicated by the Adjudication Committee and classified according to Thrombolysis in Myocardial Infarction (TIMI) major, minor, minimal, and International Society on Thrombosis and Hemostasis (ISTH) major and clinically relevant non-major bleeding (CRNM) criteria. The adjudicated results based on TIMI and ISTH classifications, and programmatically identified events (not adjudicated) according to Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) classification were used in the analyses of bleeding endpoints. GUSTO Bleed Criteria included Severe or life-threatening: Intracranial hemorrhage, or bleeding that causes hemodynamic compromise requiring intervention; Moderate: Bleeding that requires a blood transfusion, but does not result in hemodynamic compromise; Mild: Bleeding that does not meet criteria for either severe or moderate bleeding. Treatment Period=events with onset from first dose to last dose plus 2 days.

    Time frame: From first dose to first occurrence of event (Bleeding) during Treatment Period (first dose to last dose + 2 days), up to March 2011, approximately 2 years

07

Results

Posted Jan 27, 2016

Participant flow

Randomized
Participant flow — Randomized
MilestonePlacebo BIDApixaban 5 mg BID
Started36873705
Treated36433672
Completed00
Not completed36873705
Withdrew: Death8281
Withdrew: Adverse event248321
Withdrew: Emergency procedure22
Withdrew: Elective procedure2625
Withdrew: Physician decision2635
Withdrew: No longer met criteria1319
Withdrew: Withdrawal by subject178212
Withdrew: Lost to follow-up2635
Withdrew: Administrative reason by sponsor27802671
Withdrew: Poor/non-compliance3038
Withdrew: Non-specified276266
Follow Up (30 Days)
Participant flow — Follow Up (30 Days)
MilestonePlacebo BIDApixaban 5 mg BID
Started35083529
Completed33753355
Not completed133174
Withdrew: Withdrawal by subject4134
Withdrew: Lost to follow-up1327
Withdrew: Death6386
Withdrew: Non-specified1626
Withdrew: Missing end of study status01

Outcome measures

PrimaryEvent Rate of Cardiovascular Death, Myocardial Infarction, or Ischemic Stroke During the Intended Treatment Period - Randomized Participants

Event rate was percent of participants with an event of cardiovascular (CV) death, myocardial infarction (MI), or ischemic stroke (number of participants with event/number randomized) per 100 patient (100-pt) years. Study was terminated early and last patient, last visit was in Year 2. Only events confirmed by the adjudication committee were included in the analyses. CV death included deaths due to CV causes (eg, cardiogenic shock, heart failure, arrhythmia/sudden death, cardiac rupture, ischemic stroke, pulmonary embolism, venous/arterial thrombotic events) and other sudden deaths for which an alternative cause was not identified. Intended Treatment Period: the period that started on the day of randomization and ended at the efficacy cut-off date (cut-off date: the date all sites were informed that study drug should be discontinued for all participants, 18 November 2010).

Time frame:
Randomization (Day 1) to first event (CV death, MI, ischemic stroke), up to March 2011, approximately 2 years
Reported as:
Number · percentage of participants/100-pt years
Event Rate of Cardiovascular Death, Myocardial Infarction, or Ischemic Stroke During the Intended Treatment Period - Randomized Participants
percentage of participants/100-pt yearsPlaceboApixaban 5 mg BID
Event Rate of Cardiovascular Death, Myocardial Infarction, or Ischemic Stroke During the Intended Treatment Period - Randomized Participants13.9613.20
Statistical analysis
  • Placebo vs Apixaban 5 mg BID · Cox proportional hazard models · p = 0.5094 · Hazard ratio (hr): 0.95 · 95% CI 0.80 to 1.11
SecondaryEvent Rate of Unstable Angina (UA) During the Intended Treatment Period - Randomized Participants

Unstable Angina (UA) defined as worsening or recurrent severe or repetitive angina symptoms at rest lasting at least 10 minutes with at least 2 of the following: New and dynamic electrocardiogram (ECG) changes; angina symptoms leading to inpatient hospitalization; angina symptoms leading to an unplanned or urgent cardiac catheterization, with or without revascularization, that showed evidence of hemodynamically and clinically significant stenosis. Event rate was percent of participants with an event of unstable angina (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. Intended Treatment Period: the period that started on the day of randomization and ended at the efficacy cut-off date (cut-off date: the date all sites were informed that study drug should be discontinued for all participants, 18 November 2010).

Time frame:
Randomization (Day 1) to first event of UA, up to March 2011, approximately 2 years
Reported as:
Number · percentage of participants/100-pt years
Event Rate of Unstable Angina (UA) During the Intended Treatment Period - Randomized Participants
percentage of participants/100-pt yearsPlaceboApixaban 5 mg BID
Event Rate of Unstable Angina (UA) During the Intended Treatment Period - Randomized Participants4.213.95
Statistical analysis
  • Placebo vs Apixaban 5 mg BID · Cox proportional hazard models · p = 0.6702 · Hazard ratio (hr): 0.94 · 95% CI 0.70 to 1.26
SecondaryEvent Rate of Stroke During the Intended Treatment Period - Randomized Participants

Event rate was percent of participants with an event of stroke (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. Diagnosis of stroke required a new, non-traumatic, focal neurological deficit of sudden onset, lasting at least 24 hours that was not due to a readily identifiable non-vascular cause (ie, brain tumor). All strokes were classified as hemorrhagic (documentation on imaging (eg computed tomography scan or magnetic resonance imaging) of hemorrhage in the cerebral parenchyma, or a subdural or subarachnoid hemorrhage), non-hemorrhagic/ischemic stroke, ischemic stroke with hemorrhagic conversion, or type unknown. Intended Treatment Period: the period that started on the day of randomization (Day 1) and ended at the efficacy cut-off date (notification of study termination).

Time frame:
Randomization (Day 1) to first event (stroke), up to March 2011, approximately 2 years
Reported as:
Number · percentage of participants/100-pt years
Event Rate of Stroke During the Intended Treatment Period - Randomized Participants
percentage of participants/100-pt yearsPlaceboApixaban 5 mg BID
Event Rate of Stroke During the Intended Treatment Period - Randomized Participants1.851.65
Statistical analysis
  • Placebo vs Apixaban 5 mg BID · Cox proportional hazard models · p = 0.6311 · Hazard ratio (hr): 0.90 · 95% CI 0.57 to 1.40
SecondaryEvent Rate of Myocardial Infarction (MI) During the Intended Treatment Period - Randomized Participants

MI took into account whether the participant had a recent percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery. Selected key criteria: Elevation of cardiac biomarkers (eg, Creatine Kinase MB fraction (CKMB), Troponin T, Troponin I) above the upper reference limit (URL) plus ischemic symptoms, ECG changes, or imaging evidence of new loss of viable myocardium or new regional wall motion abnormality; Death of CV etiology with new ST-segment elevation or left bundle branch block (LBBB) or fresh intracoronary thrombus by angiography or at autopsy occurring before biomarkers could be obtained or before their appearance in the blood; Following a PCI, elevation of cardiac biomarkers more than 3\*URL; Following CABG surgery, elevation of cardiac biomarkers more than 5\*URL; New, significant (≥0.04 s) Q waves in ≥2 contiguous leads; Pathologic findings of acute MI. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off notice.

Time frame:
Randomization (Day 1) to first event (MI), up to March 2011, approximately 2 years
Reported as:
Number · percentage of participants/100-pt years
Event Rate of Myocardial Infarction (MI) During the Intended Treatment Period - Randomized Participants
percentage of participants/100-pt yearsPlaceboApixaban 5 mg BID
Event Rate of Myocardial Infarction (MI) During the Intended Treatment Period - Randomized Participants9.208.59
Statistical analysis
  • Placebo vs Apixaban 5 mg BID · Cox proportional hazard models · p = 0.5086 · Hazard ratio (hr): 0.93 · 95% CI 0.76 to 1.14
SecondaryEvent Rate of Stent Thrombosis During the Intended Treatment Period - Randomized Participants

Stent thrombosis: Definite stent thrombosis considered to have occurred by either angiographic or pathological confirmation; Probable stent thrombosis considered to have occurred in the following cases: any unexplained death within the first 30 days after stent implantation; irrespective of the time after the procedure, any MI that was related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause; Possible stent thrombosis considered to have occurred with any unexplained death from 30 days after intracoronary stenting until end of study (in Year 2). Event rate was percent of participants with an event of stent thrombosis (number with event/number randomized) per 100-pt years. Only events confirmed by the adjudication committee were included in the analyses. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off notice of study termination.

Time frame:
Randomization (Day 1) to first event (stent thrombosis), up to March 2011, approximately 2 years
Reported as:
Number · percentage of participants/100-pt years
Event Rate of Stent Thrombosis During the Intended Treatment Period - Randomized Participants
percentage of participants/100-pt yearsPlaceboApixaban 5 mg BID
Event Rate of Stent Thrombosis During the Intended Treatment Period - Randomized Participants2.211.61
Statistical analysis
  • Placebo vs Apixaban 5 mg BID · Cox proportional hazard models · p = 0.1502 · Hazard ratio (hr): 0.73 · 95% CI 0.47 to 1.12
SecondaryEvent Rate of Composite of Cardiovascular Death, Myocardial Infarction, Unstable Angina, or Ischemic Stroke During the Intended Treatment Period - Randomized Participants

Event rate was percent of participants with an event of CV death, MI, unstable angina (UA), or ischemic stroke (number of participants with event/number randomized) per 100-pt years. Only events confirmed by the adjudication committee were included in the analyses. Each type of event was counted once per participant, but participants could have been counted in multiple categories. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off date (notification of study termination).

Time frame:
Randomization (Day 1) to first event (CV death, MI, UA, Ischemic Stroke, up to March 2011, approximately 2 years
Reported as:
Number · percentage of participants/100-pt years
Event Rate of Composite of Cardiovascular Death, Myocardial Infarction, Unstable Angina, or Ischemic Stroke During the Intended Treatment Period - Randomized Participants
percentage of participants/100-pt yearsPlaceboApixaban 5 mg BID
Event Rate of Composite of Cardiovascular Death, Myocardial Infarction, Unstable Angina, or Ischemic Stroke During the Intended Treatment Period - Randomized Participants17.9516.92
Statistical analysis
  • Placebo vs Apixaban 5 mg BID · Cox proportional hazard models · p = 0.4317 · Hazard ratio (hr): 0.94 · 95% CI 0.82 to 1.09
SecondaryEvent Rate of Composite of Cardiovascular Death, Fatal Bleed, Myocardial Infarction, or Stroke During the Intended Treatment Period - Randomized Participants

Event rate was percent of participants with an event of CV death, fatal bleed, MI, or stroke (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. CV death included deaths due to CV causes; Diagnosis of stroke required a new, non-traumatic, focal neurological deficit of sudden onset, lasting at least 24 hours that was not due to a readily identifiable non-vascular cause; Fatal bleeding defined as bleeding that Adjudication Committee determined was the primary cause of death or contributed directly to death; MI took into account whether the participant had a recent PCI or CABG surgery. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off date (notification of study termination).

Time frame:
Randomization (Day 1) to first event (CV death, Fatal Bleed, MI, or stroke), up to March 2011, approximately 2 years
Reported as:
Number · percentage of participants/100-pt years
Event Rate of Composite of Cardiovascular Death, Fatal Bleed, Myocardial Infarction, or Stroke During the Intended Treatment Period - Randomized Participants
percentage of participants/100-pt yearsPlaceboApixaban 5 mg BID
Event Rate of Composite of Cardiovascular Death, Fatal Bleed, Myocardial Infarction, or Stroke During the Intended Treatment Period - Randomized Participants14.2713.97
Statistical analysis
  • Placebo vs Apixaban 5 mg BID · Cox proportional hazard models · p = 0.8015 · Hazard ratio (hr): 0.98 · 95% CI 0.83 to 1.15
SecondaryEvent Rate of Composite of All-Cause Death, Myocardial Infarction, or Stroke During the Intended Treatment Period - Randomized Participants

Cause of death was determined by the principal condition that caused the death, not the immediate mode of death. CV death: included deaths due to CV causes. Non-CV death: included non-CV deaths caused primarily by a malignancy, infection, bleeding, trauma, non-CV system organ failure, or non-CV surgery. Unknown: included deaths that were not attributable to one of the above categories of CV death or to a non-CV cause. MI accounted whether the participant had a recent PCI or CABG surgery. Diagnosis of stroke required a new, non-traumatic, focal neurological deficit of sudden onset, lasting at least 24 hours that was not due to a readily identifiable non-vascular cause. Only events confirmed by the adjudication committee were included in analyses. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off date (notification of study termination).

Time frame:
Randomization (Day 1) to first event (All Cause Death, MI, or Stroke), up to March 2011, approximately 2 years
Reported as:
Number · percentage of participants/100-pt years
Event Rate of Composite of All-Cause Death, Myocardial Infarction, or Stroke During the Intended Treatment Period - Randomized Participants
percentage of participants/100-pt yearsPlaceboApixaban 5 mg BID
Event Rate of Composite of All-Cause Death, Myocardial Infarction, or Stroke During the Intended Treatment Period - Randomized Participants15.6515.48
Statistical analysis
  • Placebo vs Apixaban 5 mg BID · Cox proportional hazard models · p = 0.8948 · Hazard ratio (hr): 0.99 · 95% CI 0.85 to 1.15
PrimaryEvent Rate of Confirmed Major Bleeding Using Thrombolysis in Myocardial Infarction (TIMI) Criteria During the Treatment Period - Treated Participants

TIMI Major Bleed Criteria: Fatal bleeding, intracranial hemorrhage, and clinically overt bleeding with a hemoglobin (Hgb) drop of ≥ 5 grams per deciliter (g/dL), or ≥15% absolute decrease in hematocrit. To account for transfusions, Hgb measurements were adjusted for transfusions. A transfusion of 1 unit of blood was assumed to result in an increase by 1 g/dL in Hgb or 3% in hematocrit. Event rate was percent of participants with an event of Major Bleed as per TIMI (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. Treatment Period=events with onset from first dose to last dose plus 2 days.

Time frame:
From first dose to first occurrence of event (TIMI major bleeding) during Treatment Period (first dose to last dose + 2 days), up to March 2011, approximately 2 years
Reported as:
Number · percentage of participants/100-pt years
Event Rate of Confirmed Major Bleeding Using Thrombolysis in Myocardial Infarction (TIMI) Criteria During the Treatment Period - Treated Participants
percentage of participants/100-pt yearsPlaceboApixaban 5 mg BID
Event Rate of Confirmed Major Bleeding Using Thrombolysis in Myocardial Infarction (TIMI) Criteria During the Treatment Period - Treated Participants0.912.40
Statistical analysis
  • Placebo vs Apixaban 5 mg BID · Cox Proportional Hazard model · p = 0.0006 · Hazard ratio (hr): 2.59 · 95% CI 1.50 to 4.46
SecondaryEvent Rate of Confirmed Major Bleeding Using International Society on Thrombosis and Hemostasis (ISTH) Criteria During the Treatment Period - Treated Participants

ISTH Criteria: Acute clinically overt bleeding defined as new onset, visible bleeding or signs or symptoms suggestive of bleeding confirmed by imaging techniques, which can detect the presence of blood (eg, ultrasound, CT, MRI). Major bleeding: acute clinically overt bleeding accompanied by one or more of the following: A decrease in Hgb of 2 g/dL or more over 24 hours; A transfusion of 2 or more units of packed red blood cells (RBCs); Bleeding that occurs in at least one of the following sites: intracranial, intraspinal, intraocular (within the corpus of the eye; thus, a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal; Bleeding that was fatal. Bleeding events were adjudicated by the Adjudication Committee. Event rate was percent of participants with an event (number with event/number randomized) per 100-pt years. Treatment Period=events with onset from first dose to last dose plus 2 days.

Time frame:
From first dose to first occurrence of event (ISTH major bleed) during Treatment Period (first dose to last dose + 2 days), up to March 2011, approximately 2 years
Reported as:
Number · percentage of participants/100-pt years
Event Rate of Confirmed Major Bleeding Using International Society on Thrombosis and Hemostasis (ISTH) Criteria During the Treatment Period - Treated Participants
percentage of participants/100-pt yearsPlaceboApixaban 5 mg BID
Event Rate of Confirmed Major Bleeding Using International Society on Thrombosis and Hemostasis (ISTH) Criteria During the Treatment Period - Treated Participants2.045.13
Statistical analysis
  • Placebo vs Apixaban 5 mg BID · Cox Proportional Hazard model · p = <0.0001 · Hazard ratio (hr): 2.48 · 95% CI 1.72 to 3.58
SecondaryEvent Rate of Confirmed Major Bleeding or Clinically Relevant Non-Major Bleeding (CRNM) Using ISTH Criteria During the Treatment Period - Treated Participants

ISTH Major bleed: acute clinically overt bleeding accompanied by one or more of the following: A decrease in Hgb of 2 g/dL or more over 24 hours; A transfusion of 2 or more units of packed RBCs; Bleeding that occurs in at least one of the following critical sites: intracranial, intraspinal, intraocular (within the corpus of the eye), pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal; Bleeding that was fatal. CRNM: acute clinically overt bleeding that did not satisfy additional criteria required for the bleeding event to be defined as a major bleeding event and meets at least one of the following: Hospital admission for bleeding; Physician guided medical or surgical treatment for bleeding; Change in anti-thrombotic treatment (anticoagulant or antiplatelet) therapy. Bleeding events were adjudicated by the Adjudication Committee. Treatment Period=events with onset from first dose to last dose plus 2 days.

Time frame:
From first dose to first occurrence of event (ISTH major or CRNM bleed) during Treatment Period (first dose to last dose + 2 days), up to March 2011, approximately 2 years
Reported as:
Number · percentage of participants/100-pt years
Event Rate of Confirmed Major Bleeding or Clinically Relevant Non-Major Bleeding (CRNM) Using ISTH Criteria During the Treatment Period - Treated Participants
percentage of participants/100-pt yearsPlaceboApixaban 5 mg BID
Event Rate of Confirmed Major Bleeding or Clinically Relevant Non-Major Bleeding (CRNM) Using ISTH Criteria During the Treatment Period - Treated Participants2.296.15
Statistical analysis
  • Placebo vs Apixaban 5 mg BID · Cox Proportional Hazard model · p = <0.0001 · Hazard ratio (hr): 2.64 · 95% CI 1.87 to 3.72
SecondaryEvent Rate of All Bleeding Reported by the Investigator During the Treatment Period - Treated Participants

Bleeding events were adjudicated by the Adjudication Committee and classified according to Thrombolysis in Myocardial Infarction (TIMI) major, minor, minimal, and International Society on Thrombosis and Hemostasis (ISTH) major and clinically relevant non-major bleeding (CRNM) criteria. The adjudicated results based on TIMI and ISTH classifications, and programmatically identified events (not adjudicated) according to Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) classification were used in the analyses of bleeding endpoints. GUSTO Bleed Criteria included Severe or life-threatening: Intracranial hemorrhage, or bleeding that causes hemodynamic compromise requiring intervention; Moderate: Bleeding that requires a blood transfusion, but does not result in hemodynamic compromise; Mild: Bleeding that does not meet criteria for either severe or moderate bleeding. Treatment Period=events with onset from first dose to last dose plus 2 days.

Time frame:
From first dose to first occurrence of event (Bleeding) during Treatment Period (first dose to last dose + 2 days), up to March 2011, approximately 2 years
Reported as:
Number · percentage of participants/100-pt years
Event Rate of All Bleeding Reported by the Investigator During the Treatment Period - Treated Participants
percentage of participants/100-pt yearsPlaceboApixaban 5 mg BID
Event Rate of All Bleeding Reported by the Investigator During the Treatment Period - Treated Participants16.3339.98
Statistical analysis
  • Placebo vs Apixaban 5 mg BID · Cox Proportional Hazard model · p = <0.0001 · Hazard ratio (hr): 2.36 · 95% CI 2.06 to 2.70

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Apixaban 5 mg BID—894/3,672 (24.3%)357/3,672 (9.7%)
Placebo BID—884/3,643 (24.3%)231/3,643 (6.3%)
Most frequent serious events
Showing 10 of 502
Most frequent serious events
EventApixaban 5 mg BIDPlacebo BID
Myocardial infarctionCardiac disorders150/3672158/3643
Angina unstableCardiac disorders157/3672157/3643
Cardiac failureCardiac disorders94/367282/3643
Gastrointestinal haemorrhageGastrointestinal disorders69/367223/3643
Non-cardiac chest painGeneral disorders38/367246/3643
Angina pectorisCardiac disorders37/367241/3643
Cerebrovascular accidentNervous system disorders20/367239/3643
PneumoniaInfections and infestations35/367235/3643
Atrial fibrillationCardiac disorders26/367229/3643
Coronary artery diseaseCardiac disorders22/367218/3643
Most frequent other events
Most frequent other events
EventApixaban 5 mg BIDPlacebo BID
Chest painGeneral disorders186/3672173/3643
EpistaxisRespiratory, thoracic and mediastinal disorders186/367263/3643

Baseline characteristics

Randomized participants

Age, Continuous
Age, Continuous(years)PlaceboApixaban 5 mg BIDTotal
Mean65.4 ± 11.0565.3 ± 10.8965.4 ± 10.97
Age, Customized
Age, Customized(participants)PlaceboApixaban 5 mg BIDTotal
< 65 years151215263038
≥ 65 and < 75 years142014402860
≥ 75 years7557391494
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboApixaban 5 mg BIDTotal
Female116912092378
Male251824965014
Region of Enrollment
Region of Enrollment(participants)PlaceboApixaban 5 mg BIDTotal
Russian Federation5405421082
Puerto Rico131730
Singapore111425
United States450455905
Austria5856114
Sweden5055105
Netherlands455297
China363975
Poland176177353
Korea, Republic of8889177
Brazil125125250
Slovakia302959
France221840
Bulgaria100102202
Chile302656
Colombia454388
Argentina131125256
Romania7880158
Hungary121120241
Japan9195186
Ukraine128130258
United Kingdom242145
Switzerland182038
India396398794
Spain8179160
New Zealand13922
Canada126128254
Czech Republic5454108
Turkey91120
Belgium475097
Norway262551
Finland437
Denmark373471
Italy232144
South Africa6667133
Mexico161161322
Israel7366139
Australia152338
Peru6666132
Germany8080160
Antiplatelet Therapy
Antiplatelet Therapy(participants)PlaceboApixaban 5 mg BIDTotal
Dual Antiplatelet Therapy296529685933
Single Antiplatelet Therapy7227371459
ACS Index Event
ACS Index Event(participants)PlaceboApixaban 5 mg BIDTotal
STEMI141214262838
non-STEMI158215813163
Unstable angina6936981391
08

Study locations

1,014 sites
  • Uab Medical Center
    Birmingham, Alabama 35294, United States
  • University Of Alabama At Birmingham
    Birmingham, Alabama 35294, United States
  • Heart Center Research, Llc
    Huntsville, Alabama 35801, United States
  • North Phoenix Heart Center
    Phoenix, Arizona 85020, United States
  • Sparks Regional Medical Center
    Fort Smith, Arkansas 72901, United States
  • Nea Baptist Clinic
    Jonesboro, Arkansas 72401, United States
  • Phase Care, Llc
    Alameda, California 94501, United States
  • Cardiology Consultants Of Orange County
    Anaheim, California 92801, United States
  • Beaver Medical Group
    Banning, California 92220, United States
  • Local Institution
    Chula Vista, California 91911, United States
  • Escondido Cardiology Associates, Inc.
    Escondido, California 92025, United States
  • William D. Bowden, D.O.
    Healdsburg, California 95448, United States
  • California Heart Specialists, Inc.
    Huntington Beach, California 92648, United States
  • Caring Clinical Research Corporation
    Laguna Hills, California 92653, United States
  • Eisenstein, Isaac
    Lakewood, California 90712, United States
  • Arvind J. Mehta, Md
    Long Beach, California 90806, United States
  • Local Institution
    Los Alamitos, California 90720, United States
  • Preciado Cardiology Incorporated
    Los Angeles, California 90033, United States
  • East Bay Physicians Medical Group
    Oakland, California 94609, United States
  • St. Joseph Heritage Medical Group
    Orange, California 92868, United States
  • A.R.I. Clinical Trials, Inc.
    Redondo Beach, California 90277, United States
  • Coastal Multi-Specialty Research
    Santa Ana, California 92704, United States
  • Radiant Research, Inc
    Santa Rosa, California 95405, United States
  • Harbbor-Ucla Medical Center
    Torrance, California 90509, United States
  • Rocky Mountain Cardiology
    Boulder, Colorado 80304, United States
  • South Denver Cardiology Associates Pc
    Littleton, Colorado 80120, United States
  • Drogue Medical, Llc
    Wheat Ridge, Colorado 80033, United States
  • Hartford Hospital
    Hartford, Connecticut 06102, United States
  • Alfieri Cardiology
    Newark, Delaware 19713, United States
  • Orlando Heart Specialists
    Altamonte Springs, Florida 32714, United States
  • Palm Beach Heart Institute, Llc
    Atlantis, Florida 33462, United States
  • Ronald L. Walsh, Do
    Clearwater, Florida 33756, United States
  • The Heart And Vascular Institute Of Florida
    Clearwater, Florida 33756, United States
  • Cardiovascular Specialist Of South Florida
    Davie, Florida 33324, United States
  • David E. Perloff, Md
    Ft. Lauderdale, Florida 33316, United States
  • Nature Coast Clinical Research
    Inverness, Florida 34452, United States
  • Jacksonville Heart Center, Pa
    Jacksonville, Florida 32207, United States
  • Jacksonville Center For Clinical Research
    Jacksonville, Florida 32216, United States
  • East Coast Institute For Research
    Jacksonville, Florida 32223, United States
  • The Cardio Vascular Center P.A.
    Lake Mary, Florida 32746, United States
  • Alpha Medical Research, Llc
    Melbourne, Florida 32901, United States
  • Melbourne Internal Medicine Associates (Mima)
    Melbourne, Florida 32901, United States
  • Mount Sinai Medical Center
    Miami Beach, Florida 33140, United States
  • Glenn J. Barquet, Md
    Miami, Florida 33133, United States
  • Miami Cardiology Clinical Research, L.L.C.
    Miami, Florida 33156, United States
  • Advanced Pharma Clinical Research
    Miami, Florida 33175, United States
  • Mediquest Research Group Inc.
    Ocala, Florida 34471, United States
  • Ocala Research Institute, Inc
    Ocala, Florida 34471, United States
  • Florida Heart Group
    Orlando, Florida 32803, United States
  • Orlando Heart Center
    Orlando, Florida 32806, United States
  • Palm Beach Gardens Research Center Llc
    Palm Beach Gardens, Florida 33410, United States
  • Local Institution
    Pembroke Pines, Florida 33028, United States
  • Cardiology Consultants
    Pensacola, Florida 32501, United States
  • Advent Clinical Research Centers, Inc.
    Pinellas Park, Florida 33781, United States
  • Cardio-Pulmonary Associates
    Plantation, Florida 33317, United States
  • Avivo Clin Clinical Services
    Port Orange, Florida 32127, United States
  • Heartcare Research
    Sarasota, Florida 34232, United States
  • St. Augustine Cardiology Associates
    St. Augustine, Florida 32086, United States
  • Dr Kiran C Patel Research Institute At Pepin Heart Hospital
    Tampa, Florida 33613, United States
  • Howard T. Tee, M.D., F.A.C.P., F.A.C.C.
    Vero Beach, Florida 32960, United States
  • Indian River Cardiovascular Associates, Inc
    Vero Beach, Florida 32960, United States
  • Cardiology Partners Clinical Research Institute
    Wellington, Florida 33449, United States
  • Cardiovascular Physicians Of North Atlanta
    Atlanta, Georgia 30342, United States
  • Medical College Of Georgia
    Augusta, Georgia 30912, United States
  • Columbus Cardiology Associates Pc
    Columbus, Georgia 31909, United States
  • Georgia Heart Specialists
    Covington, Georgia 30014, United States
  • Atlanta Institute For Medical Research, Inc
    Decatur, Georgia 30030, United States
  • In-Quest Medical Research, Llc
    Duluth, Georgia 30096, United States
  • Alta Pharmaceutical Research Center, Inc.
    Dunwoody, Georgia 30338, United States
  • North Georgia Medical Research
    Ellijay, Georgia 30540, United States
  • Northeast Georgia Heart Cntr, Pc
    Gainesville, Georgia 30501, United States
  • Mercer University School Of Medicine
    Macon, Georgia 31201, United States
  • Well Star Cardiovascular Medicine, Pc
    Marietta, Georgia 30060, United States
  • Southern Heart Research Institute, Llc
    Riverdale, Georgia 30274, United States
  • Memorial Hospital Of Carbondale
    Carbondale, Illinois 62901, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • University Of Chicago Hospitals
    Chicago, Illinois 60637, United States
  • Clinical Investigation Specialists, Inc
    Gurnee, Illinois 60031, United States
  • Gateway Cardiology. P.C
    Jerseyville, Illinois 62052, United States
  • Midwest Heart Foundation
    Lombard, Illinois 60148, United States
  • Local Institution
    Moline, Illinois 61265, United States
  • Illinois Heart & Lung Research
    Normal, Illinois 61761, United States
  • Heartcare Midwest
    Peoria, Illinois 61614, United States
  • Elkhart Clinic, Llc
    Elkhart, Indiana 46514, United States
  • St Margaret Mercy Healthcare Centers
    Hammond, Indiana 46320, United States
  • Krannertt Institute Of Cardiology
    Indianapolis, Indiana 46202, United States
  • R. L.Roudebush Va Medical Center
    Indianapolis, Indiana 46202, United States
  • The Care Group, Llc
    Indianapolis, Indiana 46260, United States
  • Medical Consultants, Pc
    Muncie, Indiana 47303, United States
  • Local Institution
    Valparaiso, Indiana 46383, United States
  • Mcfarland Clinic Pc
    Ames, Iowa 50010, United States
  • Iowa Heart Center
    West Des Moines, Iowa 50266, United States
  • Midwest Cardiology Associates , P.C.
    Overland Park, Kansas 66209, United States
  • Kentucky Heart & Vascular Physicians
    Ashland, Kentucky 41101, United States
  • Local Institution
    Hazard, Kentucky 41701, United States
  • Cardiovascular Associates, Psc
    Louisville, Kentucky 40205, United States
  • Research Integrity, Llc
    Owensboro, Kentucky 42303, United States
  • Alexandria Cardiology Clinic
    Alexandria, Louisiana 71301, United States
  • Clinical Research Network
    Alexandria, Louisiana 71301, United States

Showing the first 100 of 1,014 sites across 40 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Sharma A, Hagstrom E, Wojdyla DM, Neely ML, Harrington RA, Wallentin L, Alexander JH, Goodman SG, Lopes RD; Apixaban for Prevention of Acute Ischemic Safety Events APPRAISE-2 Steering Committee and Investigators. Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial. Am Heart J. 2019 Sep;215:106-113. doi: 10.1016/j.ahj.2019.05.004. Epub 2019 May 11. PubMed 31310855 ↗
  • Inohara T, Pieper K, Wojdyla DM, Patel MR, Jones WS, Tricoci P, Mahaffey KW, James SK, Alexander JH, Lopes RD, Wallentin L, Ohman EM, Roe MT, Vemulapalli S. Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome. Am Heart J. 2018 Jul;201:25-32. doi: 10.1016/j.ahj.2018.03.013. Epub 2018 Mar 28. PubMed 29910052 ↗
  • Sherwood MW, Lopes RD, Sun JL, Liaw D, Harrington RA, Wallentin L, Laskowitz DT, James SK, Goodman SG, Darius H, Lewis BS, Gibson CM, Pieper KS, Alexander JH. Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial. Am Heart J. 2018 Mar;197:1-8. doi: 10.1016/j.ahj.2017.09.020. Epub 2017 Oct 24. PubMed 29447769 ↗
  • Guimaraes PO, Lopes RD, Stevens SR, Zimerman A, Wruck L, James SK, Haque G, Giraldez RRCV, Alexander JH, Alexander KP. Reporting Clinical End Points and Safety Events in an Acute Coronary Syndrome Trial: Results With Integrated Collection. J Am Heart Assoc. 2017 Apr 24;6(4):e005490. doi: 10.1161/JAHA.117.005490. PubMed 28438739 ↗
  • Hess CN, James S, Lopes RD, Wojdyla DM, Neely ML, Liaw D, Hagstrom E, Bhatt DL, Husted S, Goodman SG, Lewis BS, Verheugt FWA, De Caterina R, Ogawa H, Wallentin L, Alexander JH. Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights From the APPRAISE-2 Trial. J Am Coll Cardiol. 2015 Aug 18;66(7):777-787. doi: 10.1016/j.jacc.2015.06.027. PubMed 26271059 ↗
  • Khan R, Lopes RD, Neely ML, Stevens SR, Harrington RA, Diaz R, Cools F, Jansky P, Montalescot G, Atar D, Lopez-Sendon J, Flather M, Liaw D, Wallentin L, Alexander JH, Goodman SG; Apixaban for Prevention of Acute Ischemic Safety Events (APPRAISE)-2 Steering Committee and Investigators. Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome. Heart. 2015 Sep;101(18):1475-84. doi: 10.1136/heartjnl-2014-307346. Epub 2015 Jun 24. PubMed 26109589 ↗
  • Mahaffey KW, Hager R, Wojdyla D, White HD, Armstrong PW, Alexander JH, Tricoci P, Lopes RD, Ohman EM, Roe MT, Harrington RA, Wallentin L. Meta-analysis of intracranial hemorrhage in acute coronary syndromes: incidence, predictors, and clinical outcomes. J Am Heart Assoc. 2015 Jun 18;4(6):e001512. doi: 10.1161/JAHA.114.001512. PubMed 26089177 ↗
  • Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, Geraldes M, Lawrence J, Harrington RA, Wallentin L; APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011 Aug 25;365(8):699-708. doi: 10.1056/NEJMoa1105819. Epub 2011 Jul 24. PubMed 21780946 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2016, 4 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2009
First posted
Jan 29, 2009
Start
Mar 2009
Primary completionActual
Mar 2011
CompletionActual
Mar 2011
Results first posted
Jan 27, 2016
Last update
Jan 27, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00831441
Collaborators
Pfizer, Duke Clinical Research Institute
Responsible party
Sponsor
First posted
Jan 29, 2009
Start date
Mar 2009
Primary completion
Mar 2011
Completion
Mar 2011
Results posted
Jan 27, 2016
Last update
Jan 27, 2016

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion